Impact of lack of suppression of glucagon on glucose tolerance in humans

American Journal of Physiology - Endocrinology and Metabolism

Volumn 277, Issue 2 40-2, 1999, Pages

  Shah, Pankaj ^a   Basu, Ananda ^a   Basu, R Rita ^a   Rizza, Robert A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Glucagon; Glucose disappearance; Glucose production; Insulin; Postprandial hypoglycemia; Type 2 diabetes

Indexed keywords

GLUCAGON; GLUCOSE; INSULIN;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GLUCONEOGENESIS; GLUCOSE TOLERANCE; HUMAN; HUMAN EXPERIMENT; HYPERGLYCEMIA; INSULIN RELEASE; MALE; PRIORITY JOURNAL;

EID: 0032877316     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.1999.277.2.e283     Document Type: Article

References (37)

1. Basu, A., A. Alzaid, S. Dinneen, A. Caumo, C. Cobelli, and R. A. Rizza. Effects of a change in the pattern of insulin delivery on carbohydrate tolerance in diabetic and nondiabetic humans in the presence of differing degrees of insulin resistance. J. Clin. Invest. 97: 2351-2361, 1996.
2. Basu, A., A. Caumo, F. Bettini, A. Gelisio, A. Alzaid, and C. Cobelli. Impaired basal glucose effectiveness in NIDDM. Contribution of defects in glucose disappearance and production, measured using an optimized minimal model independent protocol. Diabetes 46: 421-432, 1997.
3. 3H]glucose. J. Clin. Invest. 78: 1479-1486, 1986.
4. Bradley, D. C., G. M. Steil, and R. N. Bergman. Quantitation of measurement error with Optimal Segments: basis for adaptive time course smoothing. Am. J. Physiol. 264 (Endocrinol. Metab. 27): E902-E911, 1993.
5. Butler, P. C., A. Caumo, A. Zerman, P. C. O'Brien, C. Cobelli, and R. A. Rizza. Methods for assessment of the rate of onset and offset of insulin action during nonsteady state in humans. Am. J. Physiol. 264 (Endocrinol. Metab. 27): E548-E560, 1993.
6. Butler, R. C., and R. A. Rizza. Contribution to postprandial hyperglycemia and effect on initial splanchnic glucose clearance of hepatic glucose cycling in glucose-intolerant or NIDDM patients. Diabetes 40: 73-81, 1991.
7. Cherrington, A. D., P. E. Williams, G. I. Shulman, and W. W. Lacy. Differential time course of glucagon's effect on glycogenolysis and gluconeogenesis in the conscious dog. Diabetes 30: 180-187, 1981.
8. Creutz, W. O. C., N. Kleine, B. Willms, C. Orskov, J. J. Holst, and M. A. Nauck. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I (7-36) amide in Type I diabetes patients. Diabetes Care 19: 580-586, 1996.
9. Dinneen, S., A. Alzaid, D. Turk, and R. Rizza. Failure of glucagon suppression contributes to postprandial hyperglycemia in IDDM. Diabetologia 38: 337-343, 1995.
10. Ferrannini, E., R. A. DeFronzo, and R. S. Sherwin. Transient hepatic response to glucagon in man: role of insulin and hyperglycemia. Am. J. Physiol. 242 (Endocrinol. Metab. 5): E73-E81, 1982.
11. Fradkin, J., H. Shamoon, P. Felig, and R. S. Sherwin. Evidence for an important role of changes in, rather than absolute concentrations of, glucagon in the regulation of glucose production in humans. J. Clin. Endocrinol. Metab. 50: 698-703, 1980.
12. Frank, J. W., M. Camilleri, G. M. Thomforde, S. F. Dinneen, and R. A. Rizza. Effects of glucagon on postprandial carbohydrate metabolism in nondiabetic humans. Metabolism 47: 7-12, 1998.
13. Jensen, M. D., V. J. Heiling, and J. M. Miles. Effects of glucagon on free fatty acid metabolism in humans. J. Clin. Endocrinol. Metab. 72: 308-315, 1991.
14. Landau, B. R., C. A. Fernandez, S. F. Previs, K. Ekberg, V. Chandramouli, J. Wahren, S. C. Kalhan, and H. Brunengraber. A limitation in the use of mass isotopomer distributions to measure gluconeogenesis in fasting humans. Am. J. Physiol. 269 (Endocrinol. Metab. 32): E18-E26, 1995.
15. Lewis, G. F., M. Vranic, and A. Giacca. Role of free fatty acids and glucagon in the peripheral effect of insulin on glucose production in humans. Am. J. Physiol. 275 (Endocrinol. Metab. 38): E177-E186, 1998.
16. Liljenquist, J. E., and D. Rabin. Lack of a role for glucagon in the disposal of an oral glucose load in normal man. J. Clin. Endocrinol. Metab. 49: 937-939, 1979.
17. Lins, P.-E., A. Wajngot, U. Adamson, M. Vranic, and S. Efendic. Minimal increases in glucagon levels enhance glucose production in man with partial hypoinsulinemia. Diabetes 32: 633-636, 1983.
18. Magnusson, I., D. L. Rothman, D. P. Gerard, L. D. Katz, and G. I. Shulman. Contribution of hepatic glycogenolysis to glucose production in humans in response to a physiological increase in plasma glucagon concentration. Diabetes 44: 185-189, 1995.
19. McGuinness, O. P., J. Ejiofor, L. P. Audoly, and N. Schrom. Regulation of glucose production by NEFA and gluconeogenic precursors during chronic glucagon infusion. Am. J. Physiol. 275 (Endocrinol. Metab. 38): E432-E439, 1998.
20. McMahon, M., H. M. Marsh, and R. A. Rizza. Effects of basal insulin supplementation on disposition of mixed meal in obese patients with NIDDM. Diabetes 38: 291-303, 1989.
21. Mitrakou, A., D. Kelley, T. Veneman, T. Jenssen, T. Pangburn, J. Reilly, and J. Gerich. Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycemia in NIDDM. Diabetes 39: 1381-1390, 1990.
22. Nielsen, M. F., S. Wise, S. F. Dinneen, W. F. Schwenk, A. Basu, and R. A. Rizza. Assessment of hepatic sensitivity to glucagon in NIDDM. Diabetes 46: 2007-2016, 1997.
23. Orskov, L., K. G. M. M. Alberti, A. Mengel, N. Moller, O. Pedersen, O. Rasmussen, T. Seefeldt, and O. Schmitz. Decreased hepatic glucagon responses in Type 1 (insulin-dependent) diabetes mellitus. Diabetologia 34: 521-526, 1991.
24. 9]glucagon amide, a peptide antagonist of the glucagon receptor system. Proc. Natl. Acad. Sci. USA 90: 1662-1666, 1993.
25. Ritzel, R., C. Orskov, J. J. Holst, and M. A. Nauck. Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships. Diabetologia 720-725, 1995.
26. Rizza, R. A., and J. E. Gerich. Persistent effect of sustained hyperglucagonemia on glucose production in man. J. Clin. Endocrinol. Metab. 48: 352-355, 1979.
27. Sherwin, R. S., M. Fisher, R. Hendler, and P. Felig. Hyperglucagonemia and blood glucose regulation in normal, obese and diabetic subjects. N. Engl. J. Med. 294: 455-461, 1976.
28. Smith, R. A., R. Sisk, P. Lockhart, S. Mathewes, T. Gilbert, K. Walker, and J. Piggot. Isolation of glucagon antagonists by random molecular mutagenesis and screening. Mol. Pharmacol. 43: 741-748, 1993.
29. Steele, R., J. S. Wall, R. C. De Bodo, N. Altszuler, S. P. Kiang, and C. Bjerknes. Measurement of size and turnover rate of body glucose pool by the isotope dilution method. Am. J. Physiol. 187: 15-24, 1956.
30. Steiner, K. E., P. E. Williams, W. W. Lacy, and A. D. Cherrington. Effects of insulin on glucagon-stimulated glucose production in the conscious dog. Metabolism 39: 1325-1333, 1990.
31. Stumvoll, M., C. Meyer, M. Kreider, G. Perriello, and J. Gerich. Effects of glucagon on renal and hepatic glutamine gluconeogenesis in normal postabsorptive humans. Metabolism 47: 1227-1232, 1998.
32. Toft-Nielsen, M., S. Madsbad, and J. J. Holst. The effect of glucagon-like peptide I (GLP-I) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones. Diabetes 45: 552-556, 1996.
33. Tse, T. F., W. E. Clutter, S. D. Shah, and P. E. Cryer. Mechanisms of postprandial glucose counterregulation in man. Physiologic roles of glucagon and epinephrine vis-a-vis insulin in the prevention of hypoglycemia late after glucose ingestion. J. Clin. Invest. 72: 278-286, 1983.
34. Unson, C. G., A. M. Cypess, C.-R. Wu, P. K. Goldsmith, and R. B. Merrifield. Antibodies against specific extracellular epitopes of the glucagon receptor block glucagon binding. Proc. Natl. Acad. Sci. USA 93: 310-315, 1996.
35. Unson, C. G., E. M. Gurzenda, K. Iwasa, and R. B. Merrifield. Glucagon antagonists: contribution to binding and activity of the amino-terminal sequence 1-5, position 12, and the putative alpha-helical segment of 19-27. J. Biol. Chem. 264: 789-794, 1989.
36. 2 identifies glucagon antagonists from weak partial agonists/antagonists. Endocrinology 137: 3316-3322, 1996.
37. Yamamoto, T., P. Raskin, I. Aydin, and R. Unger. Effects of insulin on the response of immunoreactive glucagon to an intravenous glucose load in human diabetes. Metabolism 28: 568-574, 1979.